CELL INTELLIGENCE · 肿瘤细胞治疗研究

Inclusion Criteria:

1. Relapsed/refractory CD19BCMA positive plasma cell neoplasms and lymphomas/leukemias with plasmacytic differentiation must be assured and meet all of the following conditions:

   * Confirmation for either BCMA or CD19 positivity using immunohistochemistry or flow cytometry
   * Patients with multiple myeloma, plasma cell carcinoma, plasma cell leukemia and lymphomas/leukemias with plasmacytic differentiation who have received at least three 3 lines treatment (including anti-CD38 monoclonal antibodies, protease inhibitors, immunosuppressants, etc.) but have failed or experienced relapse
   * Patients with system light chain amyloidosis who have received at least 2 lines treatments in the past \[anti-CD38 monoclonal antibody, proteasome inhibitor (PI), or immunomodulatory drug (IMiD)\], but have failed or experienced relapse
2. Age 18-80 years, no gender restrictions
3. ECOG score ≤ 2 points
4. Expected survival period is not less than 3 months
5. HGB≥60g/L
6. Liver function and cardiopulmonary function meet the following requirements:

   * left ventricular ejection fraction≥50%
   * Oxygen saturation \>90%
   * Total bilirubin ≤1.5×ULN, ALT and AST≤2.5×ULN
7. Participants agreed to use contraception from the time of informed consent until 1 year after CAR-T cell infusion

Exclusion Criteria:

* Severe heart failure with left ventricular ejection fraction \<50%
* A history of severe lung function impairment
* Combined with other advanced malignant tumors
* Complicated with severe infection that could not be effectively controlled
* Severe autoimmune disease or congenital immune deficiency
* Active hepatitis (hepatitis B virus DNA \[HBV-DNA\] or hepatitis C virus RNA \[HCV-RNA\] test results above the lower limit of detection)
* Human immunodeficiency virus (HIV) infection or known acquired immunodeficiency syndrome (AIDS), or syphilis infection
* History of severe allergy to biological products (including antibiotics)
* Patients with other serious physical or mental illnesses or laboratory abnormalities that could increase the risk of participating in the study or interfere with the results of the study, and those who were deemed by the investigator to be unsuitable for participation in the study
* Female patients (those with fertility) are in pregnancy or lactation

主要终点：According to the incidence of treatment-related adverse events (AEs) to evaluate the safetyof CAR19BCMA CAR-T cells in the treatment of relapsed/refractory CD19+BCMA+plasma cell neoplasms and lymphomas/leukemias with plasmacytic differentiation. · Incidence of treatment-related adverse events (AEs) Description: Number and severity of adverse events graded according to CTCAE v5.0, including cytokine release syndrome (CRS) graded by ASTCT criteria and immune effector cell-associated neurotoxicity syndrome (ICANS) graded by ASBMT criteria · up to 3 years；According to the determine the Maximal Tolerable Dose(MTD) to evaluate the safety of CAR19BCMA CAR-T cells in the treatment of relapsed/refractory CD19+BCMA+ plasma cell neoplasms and lymphomas/leukemias with plasmacytic differentiation. · MTD will be determined based on DLTs observed during the first 28 days of study treatment
次要终点：According to the objective response rate (ORR) to evaluate the efficacy of CAR19BCMA CAR-T cells in the treatment of relapsed/refractory CD19+BCMA+ plasma cell neoplasms and lymphomas/leukemias with plasmacytic differentiation.

• This is a single arm treatment of CAR19BCMA CAR-T cell · EXPERIMENTAL · Experimental: CAR19BCMA-T cells Therapy Investigational product: CAR19BCMA-T cells Route of administration: Intravenous injection Lymphodepleting chemotherapy regimen: A combination of fludarabine and cyclophosphamide will be administered prior to the infusion of CD19BCMA-CAR-T cells.

This is a single arm study to evaluate the safety and efficacy of CAR19BCMA CAR-T cells in the treatment of relapsed/refractory CD19/BCMA positive plasma cell neoplasms and lymphomas/leukemias with plasmacytic differentiation.